CALCA and Hyperglycemia: More promisingly, a monoclonal antibody against CGRP was recently shown to lower hyperglycaemia and adiposity in a type-2 diabetes mouse model, suggesting targeting CGRP could have therapeutic benefits in diabetes (Halloran et al. 2020).